Chromatan Inc.
Spring House, PA
- UEI
- K2YANNA7WH31
- CAGE
- 5XGW0
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 727 Norristown Rd, Lower Gwynedd Township, PA 19002, USA
- Website
- chromatan.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| BAA contract | Food and Drug Administration | $2,334,352 |
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Delaware | 70NANB21H086 | $305,000 |
Similar vendors
About the company
Chromatan Inc. Chromatan Corporation Division is a for-profit manufacturer specializing in innovative chromatography solutions for the biopharmaceutical industry, with a focus on gene therapy applications. The company's core technology is the Continuous Countercurrent Tangential Chromatography (CCTC) platform, designed to revolutionize the purification process for recombinant adeno-associated virus (rAAV) vectors used in gene therapies. This column-free, continuous, and single-use purification system aims to significantly improve recovery, product quality, and productivity compared to traditional column chromatography methods. Chromatan has been registered with the U.S. federal government since March 2010 and has received substantial federal grant funding to support its research and development efforts in addressing significant bottlenecks in downstream processing and contributing to more efficient, cost-effective, and flexible manufacturing of life-saving gene therapy products.
Through federal grant awards, Chromatan has been involved in several key projects aimed at advancing its CCTC technology. The company received a $1,304,417 project grant from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) to commercialize its CCTC platform for rAAV purification. This project involves developing a comprehensive process development toolkit, generating pilot-scale data for multiple rAAV serotypes, integrating capture and polishing operations, and demonstrating scale-up to 50-200 L cGMP manufacturing. Additionally, Chromatan has participated in collaborative projects with the University of Delaware as a sub-grantee, focusing on developing a fully continuous downstream process for high-titer products and commercializing a new device format called the spiral sorter. These projects utilize additive manufacturing tools for process development within the CCTC framework and involve hydrodynamic modeling, scale-up, pilot-scale Protein A antibody capture campaigns, and economic analysis. Through these grant-funded initiatives, Chromatan aims to provide innovative solutions that address critical challenges in the production of gene therapies and other biopharmaceutical products.
Quick answers
Is Chromatan Inc. registered in SAM.gov?
Yes. Chromatan Inc.'s SAM.gov registration is active through May 4, 2027.
What is Chromatan Inc.'s most recent federal award?
Chromatan Inc.'s most recent federal grant award is Resubmission - development and scale-up of continuous countercurrent tangential chromatography (cctc) for next… (R44GM154572), from National Institute of General Medical Sciences (NIH), on May 15, 2024.
On GovTribe
See Chromatan Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors